Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives

By Lee James A   Bubendorf Lukas   Stahel Rolf   Peters Solange  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 625-636

Informa Healthcare

Access to resources Recommend Favorite

Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

By                  

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 889-891

Science Publishers

Access to resources Recommend Favorite

Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 3, 2010-03 ,pp. : 236-249

Bentham Science Publishers

Access to resources Recommend Favorite

Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?

By Franco Renato   Rocco Gaetano   Marino Federica Zito   Pirozzi Giuseppe   Normanno Nicola   Morabito Alessandro   Sperlongano Pasquale   Stiuso Paola   Luce Amalia   Botti Gerardo   Caraglia Michele  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 4, 2013-04 ,pp. : 407-420

Informa Healthcare

Access to resources Recommend Favorite

Anaplastic lymphoma kinase protein expression, genetic abnormalities, and phosphorylation in soft tissue tumors: Phosphorylation is associated with recurrent metastasis

By                            

Oncology Reports, Vol. 33, Iss. 4, 2015-01 ,pp. : 1667-1674

Spandidos Publications

Access to resources Recommend Favorite